JESSICA CARR: Open Payments
NPI 1225507528 · ABINGDON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,201 in 63 payments from 17 companies in 2025. Trend: 2023 $56 · 2024 $445 · 2025 $1,201
Food & beverage: $1,201
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $295 |
| Vanda Pharmaceuticals Inc. | 7 | $187 |
| ABBVIE INC. | 14 | $179 |
| Novartis Pharmaceuticals Corporation | 4 | $92 |
| Esperion Therapeutics, Inc. | 5 | $85 |
| PFIZER INC. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Alkermes, Inc. | 2 | $48 |
| Amgen Inc. | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
Products named: CAPLYTA, FANAPT, LEQVIO, NEXLETOL, VRAYLAR, QULIPTA, TRINTELLIX, LYBALVI.
Industry payments across VA — which companies pay providers there.
